新型杯芳烃表面活性剂可实现低剂量裂解灭活疫苗对流感感染的保护
研究用新型杯芳烃表面活性剂CALX133ACE替代经典去污剂Triton X-100制备流感裂解灭活疫苗,证实基于CALX133ACE的裂解HA抗原功能完整、可经SRID定量,且在4°C下至少稳定6个月;小鼠免疫含10至30倍少于商业化三价灭活疫苗Vaxigrip®或Fluviral®抗原的CALX133ACE裂解NYMC X-179A(H1N1)抗原,诱导了与商业化疫苗相当的有效保护和针对A(H1N1)pdm09感染的中和抗体应答。
要点
- CALX133ACE裂解HA抗原功能完整,可经SRID定量,4°C至少稳定6个月。
- 小鼠用含10至30倍少于Vaxigrip®或Fluviral®抗原的CALX133ACE裂解抗原免疫。
- 该免疫诱导了与商业化疫苗相当的保护和中和抗体应答。
核心结论
- 首次证明杯芳烃类去污剂可作为高效裂解剂用于生产优化的流感裂解抗原,为疫苗制造工艺的显著改进铺平道路,尤其针对当前关于禁止内分泌干扰物(如Triton X-100)的法规。
研究设计与样本
- 研究使用新型杯芳烃表面活性剂CALX133ACE作为经典去污剂的替代品制备流感灭活裂解疫苗,并免疫小鼠评估保护效果。
主要发现
- 基于CALX133ACE的裂解HA抗原功能完整,可经「金标准」方法SRID定量。
- 与基于Triton X-100的裂解一样,基于CALX133ACE的裂解抗原在4°C下至少稳定6个月。
- 小鼠免疫含10至30倍少于商业化三价灭活疫苗Vaxigrip®或Fluviral®抗原的CALX133ACE裂解NYMC X-179A(H1N1)抗原,诱导了与商业化疫苗相当的有效保护和针对A(H1N1)pdm09感染的中和抗体应答。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Influenza A viruses cause major morbidity and represent a severe global health problem. Current influenza vaccines are mainly egg-based products requiring the split of whole viruses using classical detergents such as Triton X-100, which implies certain limitations. Here, we report the use of the novel calixarene-based surfactant CALX133ACE as an alternative to classical detergents for influenza inactivated split vaccine preparation. We confirmed that CALX133ACE-based split HA antigens are fully functional and quantifiable by the "gold standard" method SRID. Additionally, as in the case of the Triton X-100-based split, the CALX133ACE-based split antigens are stable for at least 6 months at 4 °C. Moreover, immunization of mice with CALX133ACE-based split NYMC X-179A (H1N1) antigens harboring 10 to 30-fold less antigen than the commercialized trivalent inactivated vaccines Vaxigrip® or Fluviral® induced comparable efficient protection and neutralizing antibody responses against A(H1N1)pdm09 infection. Taken together, our results demonstrate for the first time the use of a calixarene-based detergent as an efficient splitting agent for the production of optimized influenza split antigens, paving the way for significant improvement in the vaccine manufacturing process, notably with regard to the current regulation on the prohibition of endocrine disruptors, such as Triton X-100.
引用
- Mandon ED, Pizzorno A, Traversier A, et al. Novel calixarene-based surfactant enables low dose split inactivated vaccine protection against influenza infection. Vaccine. 2019. PMID: 31630939. doi:10.1016/j.vaccine.2019.10.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。